Determinants of HIV-1 innate immune sensing and its role in shaping the lymphoid environment.
HIV-1 先天免疫感应的决定因素及其在塑造淋巴环境中的作用。
基本信息
- 批准号:10712594
- 负责人:
- 金额:$ 92.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-12 至 2027-06-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdjuvantAntiviral ResponseBindingBinding ProteinsBiochemicalCD4 Positive T LymphocytesCapsidCell NucleusCellsCoculture TechniquesCoupledDNADNA biosynthesisDataDendritic CellsDepositionDimerizationDiseaseEnvironmentEquilibriumEventFlow CytometryGene ExpressionGenetic EngineeringHIV-1HumanImmuneImmune systemImmunohistochemistryIn VitroInfectionInflammatoryInflammatory ResponseInnate Immune ResponseInterferon Type IKnowledgeLengthLymphoidLymphoid TissueMeasuresMechanicsMediatingModelingMolecularMucous MembraneMutagenesisNatural ImmunityOutcomePathogenesisPathologyPathway interactionsPatternPeriodicityProteinsReagentReportingRestRetroviridaeRhesusRoleRouteSIVShapesSignal TransductionSiteStructureSurfaceSystemT-LymphocyteTestingVaccine AdjuvantVaccine TherapyVariantViralViral GenesViral PathogenesisViruscytokinedata integrationdesigndimerexperimental studygastrointestinalimmune activationin vivoinnate immune sensinginsightmolecular rearrangementmucosal sitenonhuman primatepathogenpharmacologicpolyglutaminepreventrecruitresponsesensorsuperresolution microscopytargeted treatmenttranscriptomicstransmission processvaccine developmentvaccine strategyviral DNAviral transmission
项目摘要
PROJECT SUMMARY
HIV-1 has a low transmission rate and most new infections via the mucosal route are initiated by a single variant out of a viral quasispecies. Recent studies in non-human primates found that mucosal transmission foci contain infected dendritic cells, and it remains to be determined why their innate responses sometimes fail to prevent viral spread. Selective advantages that allow a virus to cross a recipient's mucosal barrier include the ability to evade restriction factors and suppress innate antiviral responses. Various HIV-1 proteins participate in these evasion tactics, including the viral capsid. After entry, the capsid binds cellular factors necessary for its transit to the nucleus and synthesis of viral DNA, while repelling restriction factors and specialized innate sensors. Over the years, we have studied several innate sensors and, most recently, our studies have focused on HIV-1- dependent activation of cyclic GAMP synthase (cGAS), a cytosolic DNA sensor. We discovered that polyglutamine binding protein 1 (PQBP1) is an adaptor required for cGAS sensing of HIV-1 DNA. PQBP1 binds to the HIV-1 capsid, thereby authenticating it as a danger signal, then recruits cGAS to the capsid as it begins to disassemble and reveal the nascent viral DNA. We assume that PQBP1 transfers cGAS to the emerging DNA by a "bait and switch" mechanism, resulting in cGAS activation and downstream gene expression. We identified both naturally occurring and genetically engineered capsid variants that activate cGAS to different levels, suggesting that capsid structure is a key determinant of this innate pathway. A critical gap in our knowledge that will be addressed by this project is how PQBP1-capsid interactions and molecular rearrangements control the strength of the cGAS signal (Aims 1 and 2). The cGAS pathway is predominanUy responsible for innate immune responses triggered by HIV-1 infection of dendritic cells, resulting in expression of antiviral factors and type I interferons as well as proinflammatory cytokines. Paradoxically, while induction of antiviral genes inhibits replication, proinflammatory cytokines can activate resting CD4+ T cells and may promote infection. We hypothesize that the strength of the cGAS signal activated by HIV-1 can tip the balance from antiviral to proinflammatory responses, thereby contributing to successful transmission. The same mechanism may also be activated in other lymphoid tissues, downstream of the initial transmission event, and may determine the course of reservoir seeding. Another critical gap in our knowledge that will be addressed by this project is how the level of cGAS activation drives the balance between antiviral and proinflammatory responses and the role of the HIV- 1 capsid in determining its magnitude, both in vitro and in vivo (Aim 3). Our findings will provide insight into the molecular events that determine the outcome of viral exposure, and these same mechanisms could also contribute to HIV-1 pathogenesis. Additionally, our findings will provide important guidance for the design of appropriate adjuvant and vaccine strategies for HIV-1 and other pathologies that involve the cGAS pathway.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SUMIT K CHANDA其他文献
SUMIT K CHANDA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SUMIT K CHANDA', 18)}}的其他基金
Center for Antiviral Medicines & Pandemic Preparedness (CAMPP)
抗病毒药物中心
- 批准号:
10514317 - 财政年份:2022
- 资助金额:
$ 92.25万 - 项目类别:
Reversing Immune Dysfunction for HIV-1 Eradication
逆转免疫功能障碍以根除 HIV-1
- 批准号:
10469447 - 财政年份:2021
- 资助金额:
$ 92.25万 - 项目类别:
Reversing Immune Dysfunction for HIV-1 Eradication
逆转免疫功能障碍以根除 HIV-1
- 批准号:
10313784 - 财政年份:2021
- 资助金额:
$ 92.25万 - 项目类别:
Reversing Immune Dysfunction for HIV-1 Eradication
逆转免疫功能障碍以根除 HIV-1
- 批准号:
10540209 - 财政年份:2021
- 资助金额:
$ 92.25万 - 项目类别:
Project 2 - Host-virus networks regulating flu replication and host responses ex vivo
项目 2 - 调节流感复制和宿主离体反应的宿主病毒网络
- 批准号:
10080715 - 财政年份:2018
- 资助金额:
$ 92.25万 - 项目类别:
Early development of small molecule dendritic cell immunopotentiators for the treatment of solid tumors
用于治疗实体瘤的小分子树突状细胞免疫增强剂的早期开发
- 批准号:
10180915 - 财政年份:2018
- 资助金额:
$ 92.25万 - 项目类别:
A Novel Conformation of the ZIKV Protease Provides a Unique 3D Scaffold for Discovering Allosteric Protease Inhibitors as Direct Anti-virals, via HT and Virtual Screening, and Protein Engineering
ZIKV 蛋白酶的新颖构象为通过 HT 和虚拟筛选以及蛋白质工程发现变构蛋白酶抑制剂作为直接抗病毒药物提供了独特的 3D 支架
- 批准号:
9757689 - 财政年份:2018
- 资助金额:
$ 92.25万 - 项目类别:
Project 2 - Host-virus networks regulating flu replication and host responses ex vivo
项目 2 - 调节流感复制和宿主离体反应的宿主病毒网络
- 批准号:
10322693 - 财政年份:2018
- 资助金额:
$ 92.25万 - 项目类别:
Project 2 - Host-virus networks regulating flu replication and host responses ex vivo
项目 2 - 调节流感复制和宿主离体反应的宿主病毒网络
- 批准号:
10322687 - 财政年份:2018
- 资助金额:
$ 92.25万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 92.25万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 92.25万 - 项目类别:
Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 92.25万 - 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 92.25万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 92.25万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 92.25万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 92.25万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 92.25万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 92.25万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 92.25万 - 项目类别:














{{item.name}}会员




